Revolutionizing Chronic Disease Treatment Through Regenerative Medicine
Source: Streetwise Reports  (9/17/24)
A regenerative medicine therapeutics company focused on developing technologies to address chronic diseases through a regenerative approach, Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) is focused on reforming healthcare through technology. See why experts and analysts are praising this company's potential. More >

Co's. Cell Pouch Performs Well in Study
Source: Dr. Douglas Loe  (9/16/24)
Data show the device keeps the incorporated therapeutic cells alive and functioning for at least five years, noted a Leede Financial Inc. report. More >

Implanted Cell Device Reaches 5 Year Milestone
Source: Stefan Quenneville  (9/16/24)
This pouch, loaded with pancreatic islet cells, is being evaluated in patients with insulin-dependent Type 1 diabetes, noted a Ventum Capital Markets report. More >

Trial Data Help Position Cell Pouch for Commercial Success
Source: Dr. Joseph Pantginis  (9/16/24)
The upside implied in the target price on this Canadian firm, developing regenerative medicine platform technologies, is 1,900%, noted an H.C. Wainwright & Co. report. More >

Is It Now Time To Buy This Biotech Stock?
Source: Clive Maund  (9/16/24)
Technical Analyst Clive Maund shares his thoughts on Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) to explain why he believes it is a good stock to accumulate, between the current price and recent lows. More >

California Biotech Reports Positive QOL Improvements in Program
Source: Dr. Jonathan Aschoff  (9/13/24)
With Ontrak Inc.'s (OTRK:NASDAQ) significant results from the first six months of data collected through its implementation of ReQoL, Roth MKM analyst Dr, Jonathan Schoff gave the company a Buy rating. More >

Biotech Co. Says New Data Show Success of Type 1 Diabetes Treatment
Source: Streetwise Reports  (9/12/24)
Clinical stage biotechnology company Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) has released new data that show success in using its Cell Pouch Transplant System to help Type 1 diabetes patients reach insulin independence. One author says the company is David taking on Goliath in the race for a cure. More >

Biotech Working on 'Functional Cure' for Type 1 Diabetes
Source: Streetwise Reports  (9/10/24)
Clinical-stage biotechnology company Sernova Corp.'s (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) Cell Pouch implantable technology can act as a "pseudo-organ," delivering therapeutic cells to the body. Find out why one newsletter author thinks the stock could deliver a big payoff for shareholders and for patients. More >

MA Biotech Reports Positive Meeting with FDA
Source: Dr. Benjamin Paluch  (9/9/24)
Replimune Group Inc.'s (REPL:NASDAQ) announced a successful pre-Biologics License Application (BLA) meeting with the FDA, according to a Roth MKM research note. More >

Healthcare Tech Firm and Leading University to Join Forces
Source: Streetwise Reports  (9/7/24)
The parties intend to develop artificial intelligence-backed solutions to a problem in healthcare, for expanded use throughout and beyond the United Kingdom. Find out why one analyst is bullish on this company and its proprietary platform. More >

Mass. Biopharma Reports Positive Data and Announces New Program
Source: Dr. David Nierengarten  (9/6/24)
Wedbush analysts noted that they would be buyers ahead of Vor Biopharma Inc.'s (VOR:NASDAQ) planned regulatory updates and likely further data readouts. More >

Pharma Co. Enrolls First Patient in Trial
Source: Dr. Joseph Pantginis  (9/5/24)
Rigel Pharmaceuticals (RIGL:NASDAQ) recently announced the enrollment of the first patient in a Phase 1b/2 trial assessing decitabine and venetoclax in combination with Rezlidhia in mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML), according to an H.C. Wainwright & Co. research note, which rated the stock a Buy. More >

Florida Biotech Completes Enrollment in 'Pivotal' Drug Trial
Source: Streetwise Reports  (8/16/24)
Florida-based Cyclo Therapeutics Inc. (CYTH:NASDAQ) says it has completed enrollment in its "pivotal" TransportNPC trial of Niiemann-Pick Type C1, a rare progressive genetic disorder. Find out why analysts are recommending the stock. More >

Long Term Care Co.'s Target Price Raised
Source: Dr. Douglas Loe  (8/14/24)
Leede Financial Inc. recently raised the target price on Extendicare Inc. (EXE:TSX) based on FQ24 financial results. More >

Promising Clinical Data and Strategic Partnerships Propel Oncology Co.
Source: Streetwise Reports  (8/9/24)
Elevation Oncology Inc.(ELEV:NASDAQ) reported its second-quarter 2024 financial results on August 6, highlighting significant progress in its clinical trials and ongoing business achievements. Read on to see why three experts believe this stock is a Buy. More >

AI Healthcare Co. Signs Partnership With Large Regional Health Plan
Source: Dr. Jonathan Aschoff  (8/9/24)
Ontrak Inc. (NASDAQ: OTRK) announced it had signed a two-year strategic partnership with a large, northeast regional health plan focused on the plan's New York State members. This development comes as the company continues to rebuild its client base following a significant customer loss in Q1 2024, noted a Roth MKM research note. More >

Boston Biotech Reports Promising Interim Data
Source: Dr. Swayampakula Ramakanth  (8/7/24)
Interim efficacy data reported for Elevation Oncology Inc.'s (ELEV:NASDAQ) EO-3021 as a monotherapy is competitive and potentially could be superior as a combination therapy, according to an H.C. Wainwright & Co. research note. More >

New Firmware Update Enhances Counter-Drone Capabilities
Source: Streetwise Reports  (8/6/24)
DroneShield Ltd. (DRO:ASX; DRSHF:OTC) has released its latest firmware update for its full range of Radio Frequency (RF) sensors. Read about what this advancement means for the technological power of the company's product line. More >

AI Healthcare Co. Creates AI Pharmacy Assistant
Source: Streetwise Reports  (8/2/24)
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) announced it will roll out a new AI (artificial intelligence) Pharmacy Assistant to support pharmacists. One analyst says the company has positioned itself as a "central go-to resource." More >

Exercised Warrants Show Confidence in AI-Driven Healthcare Innovations
Source: Streetwise Reports  (7/29/24)
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has successfully seen the exercise of nearly 800,000 warrants issued on conversion of special warrants in June for gross proceeds of about CA$500,000. See why one technical analyst rates this stock a Buy as the company solidifies its investor confidence. More >

Analyst Says CA Pharma Underappreciated by Investors
Source: Patrick Trucchio  (7/23/24)
Arrowhead Pharmaceuticals Inc. (ARWR:NASDAQ) recently hosted a webinar going over its pulmonary programs. Read on to see why an H.C. Wainwright & Co. analyst believes the company is underappreciated by investors. More >

Analyst's Target Price for Biotech Massively Higher Than Current Price
Source: Dr. Leland Gershell  (7/22/24)
Oppenheimer & Co. recently put out a report that gave NuCana Plc. (NCNA:NASDAQ) a target price of US$150. The stock is currently trading at US$2.98. Read on to see why the analyst has given the company such a massive target price. More >

Study Shows 93% Cough Suppression With Co.'s Drug
Source: Streetwise Reports  (7/18/24)
Clinical-stage pharmaceutical development company Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) announced the drug ifenprodil achieved a 93% reduction in median cough count in an acute guinea pig citric acid challenge study. Find out why one analyst says this stock is headed for a "major bull market." More >

Could This Stock Be the Next Bellus Cough Treatment?
Source: Clive Maund  (7/17/24)
Technical Analyst Clive Maund shares an extensive overview of Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) to explain why he believes it is a Strong Buy. More >

LA Biotech Unveils New Patented Nicotinamide Riboside Chloride
Source: Dr. Raghuram Selvaraju  (7/15/24)
"The advent of NIAGEN IV could usher in a powerful new tailwind for revenue growth at ChromaDex Corp. (CDXC:NASDAQ)," noted an H.C. Wainwright & Co. report. More >